Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNotes PayablesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CNBX Pharmaceuticals (CNBX) Liabilities and Shareholders Equity (2016 - 2025)

CNBX Pharmaceuticals (CNBX) has disclosed Liabilities and Shareholders Equity for 13 consecutive years, with $11162.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 49.96% year-over-year to $11162.0, compared with a TTM value of $98874.0 through Nov 2025, down 66.78%, and an annual FY2025 reading of $18437.0, down 41.25% over the prior year.
  • Liabilities and Shareholders Equity was $11162.0 for Q4 2025 at CNBX Pharmaceuticals, down from $18437.0 in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $5.0 million in Q1 2021 and bottomed at $11162.0 in Q4 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $994944.4, with a median of $480545.5 recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity soared 39.08% in 2021, then tumbled 94.24% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $2.1 million in 2021, then plummeted by 71.25% to $609509.0 in 2022, then tumbled by 36.44% to $387402.0 in 2023, then crashed by 94.24% to $22308.0 in 2024, then tumbled by 49.96% to $11162.0 in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for CNBX at $11162.0 in Q4 2025, $18437.0 in Q3 2025, and $18615.0 in Q2 2025.